Asian markets ended mostly higher on Friday due to positive news surrounding potential vaccines to treat Covid-19 fanned optimism about a speedy global economic revival. AstraZeneca is likely to run an additional global trial to assess the efficacy of its Covid-19 vaccine using a lower dosage, its chief executive was quoted as saying amid questions over the results from its late-stage study. Further, easing US political uncertainty after President-elect Joe Biden's transition to the White House also lifted sentiment. Chinese shares climbed after data showed the country's industrial profits advanced 28.2 percent on a yearly basis in October, marking the sixth consecutive rise in profits as the economy showed signals of robust rebound from the corona virus driven downturn.
Asian Indices | Last Trade | Change in Points | Change in % |
Shanghai Composite | 3,408.31 | 38.58 | 1.14 |
Hang Seng | 26,894.68 | 75.23 | 0.28 |
Jakarta Composite | 5,783.34 | 23.42 | 0.41 |
KLSE Composite | 1,607.59 | -4.52 | -0.28 |
Nikkei 225 | 26,644.71 | 107.40 | 0.40 |
Straits Times | 2,855.82 | -1.66 | -0.06 |
KOSPI Composite | 2,633.45 | 7.54 | 0.29 |
Taiwan Weighted | 13,867.09 | 21.43 | 0.15 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: